Recently, the Dlxfamily of homeobox genes have been identified as candidates for regulating patterning and differentiation of the forebrain.
We have made a polyclonal antiserum to the protein product of the D/x-Z gene. Using this antiserum,
we have characterized the spatial and temporal pattern of DLX-2 protein expression during murine development and in the adult mouse brain. These studies demonstrate that, like the mRNA from the D/x-2 gene, DLX-2 protein is expressed in mouse embryonic forebrain, limbs, tail, genital tubercle, and branchial arches. Within the embryonic forebrain, DLX-2 protein is expressed within specific transverse and longitudinal domains. Analysis of expression within the wall of the forebrain shows that DLX-2 is expressed in proliferative regions including the ventricular and subventricular zones. DLX-2 is expressed in the same cells as MASH-l, a marker of relatively undifferentiated cells, but in a reciprocal fashion to MAP-2, a marker of terminal neuronal differentiation.
A number of DLX-2-expressing cells, but not all, can be labeled with bromodeoxyuridine (BrdU). Using the patterns of DLX-2, MASH-l, MAP-2 expression, and bromodeoxyuridine incorporation, we identify four molecularly distinct populations of cells that may correspond to different stages of neuronal differentiation in the mouse basal forebrain, in which DLX-2 is expressed at the transition from proliferation to terminal differentiation. [Key words: DLX-2, MASH-1, MAP-2, bromodeoxyuridine, antibody, homeobox, forebrain, development, differentiation]
The mammalian forebrain develops from the prosencephalon at the rostra1 end of the neural tube and consists of structures such as the cerebral cortex, basal ganglia, hippocampus, hypothalamus, and thalamus. Despite the complexity of its functioning, recent studies have shown that the mammalian forebrain shares developmental strategies with simpler systems. In particular, genes from the homeobox, basic helix-loop-helix, Wnt, growth factor, and steroid receptor gene families have been found to have specific spatial and temporal expression patterns in the forebrain (reviewed in Puelles and Rubenstein, 1993; Rubenstein and Puelles, in press ). These gene families have proven roles in regulating pattern formation and cell differentiation in both invertebrates and vertebrates (Lawrence, 1992; McGinnis and Krumlauf, 1992) .
The mammalian hindbrain, like the invertebrate embryo, may have a segmental blueprint (Lumsden and Keynes, 1989; Keynes and Lumsden, 1990) . In the hindbrain, the segments are called rhombomeres. Rhombomere identity in the hindbrain is thought to be determined in part by the expression of the Hox family of genes (reviewed in Krumlauf et al., 1993) . On a morphologic basis, the forebrain has a less clear segmental organization. The expression patterns of putative regulatory genes recognize boundaries that are consistent with a segmental organization of the forebrain (Bulfone et al., 1993a; Puelles and Rubenstein, 1993) . In the forebrain, the repeating segments are called prosomeres. We have hypothesized that the identity of the prosomeres is codified by master regulatory genes, including the Dlx genes. In addition, Figdor and Stem (1993) have shown that the prosomemeric boundaries in the diencephalon may correspond to borders of cell migration and thus are like the segmental borders in the Drosophila embryo (Lawrence, 1992) and mammalian hindbrain (Fraser et al., 1990) , which are boundaries that restrict cell migration and cell lineage.
To understand patterning and differentiation in the mouse forebrain, we previously isolated a collection of genes that are preferentially expressed in the developing forebrain (Porteus et al., 1992) . From this collection of about 500 different genes, we have identified several, including Tes-1, that are expressed both in regionally and temporally restricted patterns in the embryonic forebrain (Porteus et al., 1991 (Porteus et al., , 1992 . Tes-I has since been renamed Dlx-2, as it belongs to a family of vertebrate homeobox genes (Porteus et al., 1991; Price et al., 1991; Robinson et al., 1991; Beauchemin and Savard, 1992; Ekker et al., 1992; Pa-_ I palopulu and Vintner, 1993) that are homologous within the -_ homeobox to the Drosophila melanogaster gene distal-less (011) the DLX-2 protein to define the characteristics of the cells that . Previously, using in situ RNA hybridization, we and others showed that Dlx-2 has sharp borders of express DLX-2 protein.
In particular, we use the polyclonal expression in the embryonic forebrain (Porteus et al., 1991; Robinson et al., 1991; Bulfone et al., 1993a,b) . Moreover, the antiserum to compare the expression of DLX-2 at a cellular expression pattern of Dlx-2 has some remarkable similarities to the expression of distal-less in Drosophila, suggesting that level with the expression of MASH-l, a protein marker of a these genes have conserved both structural and expression information through evolution (Bulfone et al., 1993b) .
relatively undifferentiated neuronal state (Guillemot et al., 1993) ,
In addition to understanding pattern formation, we also wanted to use our collection of genes to study differentiation in the forebrain. In this reDort. we use polvclonal antiserum against MAP-2, a protein marker of terminal neuronal differentiation (Gamer et al., 1988) , and with the incorporation of bromodeoxyuridine (BrdU) into mitotically active cells during S-phase. Based upon this analysis, we identify four molecularly distinct populations of cells in the embryonic forebrain and outline a sequence of stages involving transitory DLX-2 expression during early differentiation in the embryonic forebrain.
Affigel-10 for 4 hr at 4"C, resulting in the covalent attachment of DLX-2 polypeptide to the Affigel-10 matrix. The matrix was washed with 20 ml of PBS and stored under PBS containing 0.2% sodium azide at 4°C. We call this column the Georg column. The C-terminal 124 amino acids of DLX-2 was subcloned into pGEX-2T (Promega), a bacterial expression vector creating glutathione-B transferase-DLX-2 fusion protein. This expression construct is called was made by inserting the 113 kilobases of D&-2 cDNA from -300 pM659. The GST-DLX-2 fusion protein was purified as above using a relative to the initiation codon to the termination codon (Porteus et al.. nickel-charged column and used to create an Affigel-1 O-coupled column at 2000 x g.-The pellet was resuspended in 20 ml of PBS (130 mM as described above. This column is called the Hack1 column. In sumNaCl, 7 mM Na,HPO,, 3 mM NaHPO,) and stored at -70°C. Aliquots mary, the Georg column contains the carboxyl-terminal199 amino acids (C-199) of DLX-2, while the Hack1 column contains the carboxyl-terminal 124 amino acids (C-124) of DLX-2 as a fusion protein with of the resuspended sera were affinity purified by passing three times at glutathione-S-transferase.
4°C over either the Georg or Hack1 affinity columns. Anti-Cl99 was Afinity purification of DLX-2 antiserum. Antiserum (10 ml) from rabbit 2 was extracted by making 50% saturated with ammonium sulfate purified using the Georg column, while anti-Cl24 was purified using and incubatinn at 4°C for 60 min followed bv centrifunation for 10 min the Hack1 column. After passing the same serum aliquot over the column three times, the column was washed with 10 column volumes (10 ml) of 1 M NaCl at room temperature. Enriched anti-DLX-2 antiserum was eluted by washing the column with 10 column volumes of 0.2 M glycine HCl (pH 2.2) at 4°C. The column was restored by washing with copious amounts of PBS (>50 ml) until the flow-through had a pH of 7.4. The eluate was neutralized to pH 7.0 with unbuffered 1 M Tris. The Trisglycine solution, containing enriched anti-DLX-2 antiserum, was dialyzed overnight with at least three buffer changes at 4°C against PBS and stored at -70°C.
Western analvsis. A eukaryotic expression plasmid, called pM640,
Materials and Methods
Generation of DLX-2 polyclonal antiserum. Using standard molecular biology techniques (Sambrook et al., 1989 ) Dlx-2 cDNA was digested with HindIII/BamHI, releasing an 800 bp fragment encoding the C-terminal 199 amino acids of DLX-2. The fragment was subcloned into the BamHI site ofpET Id (Novagen), creating pM548. We transformed BL2lDE3pLysS Escherichia coli with pM548 to create strain M565. Recombinant DLX-2 protein was generated by inoculating at a 1:lOO dilution of an overnight culture of M565 in LB medium containing ampicillin (50 &ml)and chloramphenicol (50 pg/ml) and incubating at 37°C for 2-3 hr. Induction of recombinant DLX-2 was performed by adding 1 mM isopropyl+thiolgalactopyranoside (IPTG, Sigma), incubating for 30 min, and then adding Rifampin (200 &ml). The culture was allowed to grow for 2 hr. The bacterial cells were pelleted by centrifugation, resuspended in lysis buffer (PBS/l% Triton X-100), and then sonicated on ice. Recombinant DLX-2 was purified by polyacrylamide gel electrophoresis (SDS-PAGE). The gel region containing recombinant DLX-2 was excised, soaked in 0.1% SDS, 50 mM Tris Cl 199 1) into pSVK3 (Promega). Expression in eukaryotic cells is driven by an SV40 promoter and enhancer in this construct. COS cells were transfected with pM640 and pCH 110, a plasmid that contains the p-palactosidase gene under the control of the SV40 promoter, or with pCH 110 alone. Transfections were performed according to standard techniques by the DEAE-dextran method (Sambrook et al., 1989) . Transfected cells were harvested 72 hr after transfection by lysing in SDS-load buffer (10% glycerol, 5% fl-mercaptoethanol, 2.3% SDS, 67 mM Tris Cl pH 6.8) and stored at -70°C. COS cells transfected with both pM640 and DCH 110 are called COS( +) cells and cells transfected with onlv DCH 110 -. , Iare called COS(-) cells. Analysis of P-galactosidase expression was performed by layering substrate in molten agarose ( 1% agarose, PBS, 2 mM MgCl,, 2 mg/ml X-gal) over paraformaldehyde-fixed and transfected cells. This procedure showed that the percentage of cells transfected in the COS(-) and COS(+) cells was equal (data not shown).
Tissue extracts from E14.5 mouse embryos were made from freshly dissected mouse forebrain, spinal cord, and liver in PBS at 4°C. DispH 7.4, 1 mM EDTA, 100 mM NaCl for 2 d at 4°C and then lyophilized. The lyophilized material was given to BabCo Inc. (Richmond, CA) and Generation of DLX-2 affinity columns for purification of antiserum.
injected into two rabbits according to their standard protocol. Affinity columns were made by mixing purified DLX-2 protein with AffiGel 10 matrix (Bio-Rad) according to manufacturer's specifications. Briefly, the affinity column was made by expressing the carboxyl-terminal 199 amino acid DLX-2 polypeptide in bacteria as described above. The DLX-2 polypeptide was purified by lysing bacteria in binding buffer (6 M urea, 5 mM imidazole, 500 mM NaCl, 20 mM Tris Cl pH 7.9) followed by sonication. The lysate was then loaded onto a Nickel-charged column from Novagen, made and equilibrated according to manufacturer's specifications. The bacterial lysate was adsorbed to the nickel-charged column and the eluate was discarded. DLX-2 polypeptide bound specifically to the nickel-charged column on the basis of the eight consecutive histidine residues in the carboxyl-terminal portion of the polypeptide. The adsorbed column was washed with 10 column volumes (15 ml) of wash buffer (6 M urea, 60 mM imidazole, 500 mM NaCl, 20 mM Tris Cl pH 7.9). The DLX-2 polypeptide was eluted with 10 column volumes (15 ml) of strip buffer (6 M urea, 100 mM EDTA, 500 mM NaCl, 20 mM Tris Cl pH 7.9). The eluate was dialyzed into storage buffer (300 mM KCl, 1 mM EDTA, 50 mM HEPES pH 7.6) and stored at -70°C. Purified DLX-2 was mixed with 1 ml of sected tissue was then placed in extract buffer (10% glycerol, 5% @-mercantoethanol. 2.3% SDS. 67 mM Tris Cl DH 6.8). and sonicated (four Western analysis was performed essentially according to standard techniques (Sambrook et a1.,1989) . In brief, tissue extract from either times for 30 set each) at4"C, and stored at -70°C.
transfected COS cells, purified bacterially expressed protein, or E14.5 tissue was heated to 95°C for 5 min, loaded onto a 12.5% polyacrylamide denaturing gel, and separated by electrophoresis. After electrophoresis, the protein was transferred to 0.2 I.~M nitrocellulose (Bio-Rad) by electrophoretic transfer overnight at 4°C at 35 mA. Staining was performed bv first blockina in PBST (PBS with 0.2% Tween-20) with 4% dried milk for 30 min-followed by incubation with anti-DLX-2 antiserum in PBS at 1: 100 dilution for 60 min. The filter was then washed three times for 10 min in PBST containing 4% dried milk. Secondary alkaline phosphatasexonjugated goat anti-rabbit antibody (Pharmacia) was added in PBST at a concentration of 1: 10,000 and incubated for 60 min at room temperature. The filter was then washed three times for 10 min in TBST (10 mM Tris Cl pH 7.4, 150 mM NaCl, 0;2% Tween-20). Color development was performed by incubating the filter in the dark in 100 mM Tris Cl pH 9.5, 100 mM NaCI, 5 mM MgCl, containing nitro blue tetrazolium (NBT) and 5-bromo-4-chloro-3-indolyl-phosphate (BCIP) as alkaline phosphatase color substrates until the appropriate level of staining was obtained. The color reaction was terminated by rinsing the et al. l Distinct Cel l Populations Defi ned by DLX-2 Expression filter three times with distilled water and the filter was stored dry in the dark. Immunohistochemistry. Sections (10 pm) of mouse embryos or postnatal mouse brains were prepared by cryostat sectioning as previously described (Porteus et al., 199 1) . Sections were stained in the following manner. Sections were fixed with freshly prepared 4Oh paraformaldehyde/PBS for 60 min at room temperature followed by washing three times for 5 min in PBS. Sections were blocked by incubating with 100% sheep serum for 30 min at room temperature. The sheep serum was removed, and primary anti-DLX-2 antiserum was added at a dilution of 1:50 for anti-Cl99 or 1:20 for anti-Cl24 in primary buffer (PBS, 10% sheep serum, 0.05% thimerosal) and incubated overnight at 4°C. After the overnight incubation, the sections were washed three times for 5 min with PBS at room temperature. Next, secondary biotinylated-conjugated sheep anti-rabbit antibody (1:200 in PBS/IO% sheep serum) was added and incubated at room temperature for 60 min. The sections were washed three times for 5 min in PBS. Tertiary horseradish peroxidase+onjugated streptavidin (1: 1000 in PBS) was added and incubated for 60 min at room temperature. The sections were washed three times for 5 min each in PBS. Staining was performed by incubating the sections at room temperature in color reagent solution (0.05% diaminobenzidine, 0.006% H,O,) until appropriate staining was obtained, usually 20-30 min. The staining was terminated by washing in water and the sections were dehydrated through graded ethanols into xylene and then coverslipped with Permount and stored at room temperature in the dark.
MASH-1 immunohistochemistry was essentially performed as previously described (Lo et al., 1991) . Briefly, after fixation and washing as described above for DLX-2 immunohistochemistry, sections were blocked with undiluted horse semm and incubated with anti-MASH-l monoclonal antibody at a 1:4 dilution overnight at 4°C in primary buffer. Sections were then washed three times for 5 min at room temperature in PBS. Secondary antibody and tertiary antibodies were incubated and washed according to manufacturer's specifications for the Vectastain anti-mouse staining kit (Vector Labs). Color reaction and mounting were performed as described for DLX-2 immunohistochemistry described above.
MAP-2 immunohistochemistry was performed by fixing, washing, and blocking sections as described above for DLX-2 immunohistochemistry. Sections were incubated in primary antibody (monoclonal mouse anti-MAP-2 (Boehringer-Mannheim) diluted to 1:lOO in primary buffer) overnight at 4°C. Sections were then washed three times in PBS for 5 min at room temperature. Sections were then incubated in secondary antibody (goat anti-mouse horseradish peroxidase conjugated at 1:200 in PBS/ 10% sheep sera) for 60 min at room temperature. Washing, color reaction, and mounting were then performed as described above for DLX-2 immunohistochemistry. Double immunofluorescence was performed by fixing and washing the sections as described above and then incubating in primary solution (anti-Cl24 at 1:20, anti-MASH-l at 1:4, 10% sheep serum, 0.05% thimerosal, PBS) overnight at 4°C. Sections were washed three times for 5 min at room temperature in PBS. Sections were then incubated in secondary solution (PBS, 1 OI sheep sera, 1: 100 fluorescein-conjugated anti-mouse IgG, 1: 10 rhodamine-conjugated anti-rabbit IgG) for 60 min at room temperature in the dark. Sections were then washed in PBS four times for 5 min each at room temperature in the dark, with the last wash containing 10 &ml 4',6-diamidino-2'-phenylindole (DAPI). Slides were coverslipped with Glycergel mounting solution and stored at -70°C in the dark. Using this technique, MASH-l protein is labeled with a fluorescein-conjugated antibody, DLX-2 protein is labeled with a rhodamine-conjugated antibody, and cell nuclei are stained with DAPI. Photography was performed using a Nikon Optiphot-2 microscope with appropriate filters in the dark.
Bromodeoxyuridine pulse labeling and detection. Pregnant mice at E12.5 were injected intraperitoneally with 100 &gm body weight of 5-bromo-2'-deoxyuridine (BrdU) in 0.9% NaCl. The injected mice were sacrificed 60 min after injection and the embryos were harvested, stored, and sectioned as previously described (Porteus et al., 199 1) .
BrdU staining was performed as follows. The sections were fixed in 4% paraformaldehyde/PBS for 30 min at room temperature. The sections were then denatured in 2 N HCl for 1 hr at room temperature and then neutralized by washing at least six times in PBS for 5 min each at room temperature. The sections were stained using mouse monoclonal anti-BrdU antibody (Becton-Dickinson) at 1: 100 and the anti-mouse Vectastain detection kit from Vector labs (Burlingame, CA) as described above for MASH-1 immunohistochemistry.
Mouse monoclonal antiBrdU antibody was obtained from Becton-Dickinson and used at a concentration of 1: 100.
Image analysis. Images for Figures 2, 3, 4, 5, 6, 7, 9 , and 10 were captured and processed using a Nikon Optiphot-2 microscope and IM-AGE 1.52 software and PERSUASION 2.1 software. Figure 1 was created by capturing and processing the image with a Nikon 35 mm camera and IMAGE 1.52 and PERSUASION software. Figure 8 was made by photographing through a Nikon Optiphot-2 microscope using appropriate filters to capture fluorescein and rhodamine fluorescence using Kodachrome 400 film.
Results
Production and characterization of DLX-2 antiserum We expressed the carboxyl-terminal 199 amino acids of the Dlx-2 gene in bacteria. The deduced polypeptide contains a stretch of eight consecutive histidines and the homeobox, predictions that we tested in two ways. The recombinant protein bound to nickel-linked affinity columns, consistent with the presence of the polyhistidine domain (data not shown). Likewise, gel shift experiments showed that the recombinant protein specifically bound to an oligonucleotide encoding a consensus homeobox binding sequence but not to nonconsensus sequences (Porteus, Liu, and Rubenstein, unpublished observations) .
Recombinant DLX-2 protein was purified and injected into rabbits. The resulting serum was purified using either a column linked to the carboxyl-terminal 199 amino acids, which includes the homeodomain, or a column linked to the carboxyl-terminal 124 amino acids, which contains only the carboxyl-terminal eight amino acids of the homeodomain but no other sequences with significant homology to proteins currently in the GenBanW EMBL databases. In addition, outside the homeodomain, there is no significant homology between DLX-1, a second murine member of the DLX family of homeobox genes, and DLX-2 (Price et al., 1991 ; data not shown). Thus, antiserum purified against the second column would not be expected to cross-react with DLX-1. Antiserum purified with the first column is called anti-Cl 99 and antiserum purified with the second column is called anti-C124. We performed a series of Western analyses to test the specificity of the antisera. We found that anti-Cl99 bound recombinant DLX-1 with approximately loo-fold less affinity than DLX-2 and anti-Cl 24 bound DLX-1 with at least lOOO-fold less affinity than DLX-2 (Fig. 1) . We then transfected COS cells with the full coding region of the Dlx-2 cDNA. Figure 1 shows that anti-C 124 binds to a 45 kDa band in COS cells that have been transfected with the Dlx-2 cDNA but not in cells that have been transfected with a control plasmid. Figure 1 shows that anti-C 124 recognizes an identically sized 45 kDa band in embryonic day 14.5 (E 14.5) forebrain but not in E 14.5 spinal cord or liver. Western analysis of E14.5 forebrain, spinal cord, and liver with anti-C 124 shows a number of bands that are stained in all three lanes. These bands are probably nonspecific and immunohistochemical analysis of an E 14.5 mouse embryo shows there is no staining above background in the spinal cord or the liver (Fig. 1) . Thus, while anti-Cl24 is not completely specific for DLX-2, the cross-reactivity does not compromise the use of the antiserum for immunohistochemistt-y. While the anti-Cl 24 serum recognizes a 45 kDa band, the predicted molecular weight of DLX-2 is 36 kDa. These data suggest either that DLX-2 is posttranslationally modified (e.g., El45 spinal cord (lane 5) and liver (he 6). Lane 7 contains a DLX-2 polypeptide (C124) purified from bacteria that was used to generate the anti-DLX-2 antiserum, while lane 8 contains a purified bacterially expressed full-length DLX-1 glutathione-S-transferase fusion protein (there is -lOO-fold more protein in lane 8 than in lane 7). The urroys to the left of lanes 7-9 mark the 27 kDa DLX-2 and 53 kDa DLX-1 bands. The right panel shows immunohistochemistry performed on a parasagittal section of a mouse El45 embryo. In this section, there is no labeling above background of the spinal cord and liver while there is strong labeling of the medial ganglionic eminence (MGE), lateral ganglionic eminence (LGE), and the ectodermal cells of the frontonasal prominence (FNZ'). Thus, the faint bands seen in common in the liver, spinal cord, and forebrain do not interfere with specific immunohistochemical staining and probably contribute to the background staining. See Table 1 for the abbreviations used in this and all subsequent figures. Scale bar, 240 pm. anomalously in our gel system, probably secondary to intrinsic protein structure. In sum, the series of Western blots demonstrate that anti-C 124 recognizes DLX-2 and can be used reliably to stain tissues to determine the expression pattern of the DLX-2 protein. We observed no differences in the staining patterns generated by anti-Cl24 or anti-Cl 99 on tissue sections. With both antisera we observed strong nuclear staining, suggesting that DLX-2 is localized to the nucleus. In DLX-2-expressing cells, there is often scant cytoplasm, and thus we cannot rule out that DLX-2 protein is present in the cytoplasm as well.
Using anti-Cl24 and anti-C199, we characterized the expre.ssion pattern of DLX-2 protein through development. The following sections show DLX-2 protein is expressed in a regionally restricted pattern in the developing forebrain, and it is expressed in the distal aspects of embryonic structures.
Expression of DLX-2 in the forebrain Our analysis of DLX-2 expression spans from E 10.5 to the adult. From E10.5 to E14.5, DLX-2 is expressed in two regions of the forebrain: domains I and II (Bulfone et al., 1993b) . The caudal zone, domain II, extends axially from the area of the suprachiasmatic nucleus (SCH) through the hypothalamic cell cord (HCC) and posterior entopeduncular area (PEP) into the ventral thalamus (VT), and terminates abruptly at the zona limitans (ZL), the boundary zone that separates the dorsal thalamus (DT) from the ventral thalamus. Domains I and II are separated by a strip of DLX-2-negative tissue, called the optoeminential zone, which extends from the eminentia thalami (EMT) to the optic stalk (Bulfone et al., 1993b) . Here, a small gap of expression is generally found (Fig. 3) , although in some planes of section domains I and II are connected by a thin strip of DLX-2-expressing cells (see Fig. 2C ). The rostra1 zone, domain II, stretches from the junction of the lateral ganglionic eminence with the cerebral cortex down through the preoptic area and terminates in the region of the optic stalk. This domain does not extend into the caudal ganglionic eminence in the caudal telencephalon. Both domains I and II are continuous from left side to right side across the midline at the lamina terminalis. Figure 3 demonstrates that the patterns of expression in the forebrain at E12.5, E13.5, and E14.5 are essentially indistinguishable. At El 6.5, by a process of cell division within a limited space, the forebrain is beginning to fold and appears different from the forebrain from earlier ages shown in Figure 3 . Prior to E16.5, DLX-2 expression has many sharp borders of expression, for instance, between the ventral and dorsal thalamus, the cerebral cortex and lateral and medial ganglionic eminence, and the anterior entopeduncular area (AEP) and eminentia thalami (EMT). Some of these borders, for example, between the ventral and dorsal thalamus and between the AEP and EMT, remain sharp at E16.5 and throughout development (Fig. 4) . Other borders, such as between the lateral ganglionic eminence and cerebral cortex and between the lateral ganglionic eminence and olfactory bulb, however, are crossed by DLX-2 expression at E 16.5 (Fig.  4) . The expression of DLX-2 in the olfactory bulb represents an extension of domain II at this age. Figure 4 illustrates this point in an E16.5 embryo and also demonstrates that while DLX-2 expression remains strong in the rostra1 expression domains, it is beginning to weaken in more caudal domains, particularly the ventral thalamus, at E16.5.
Prior to E16.5, the cerebral cortex is conspicuously negative for DLX-2 expression. At E16.5, however, DLX-2 is expressed in dispersed cells of the subventricular, intermediate, subplate, and marginal zones of the cerebral cortex; these cells are continuous with DLX-2-positive regions of the lateral ganglionic eminence and olfactory bulb (Fig. 4) . In addition, many cells of the olfactory bulb express DLX-2. Whereas DLX-2 is expressed in all ceils of the subventricular zone in the ganglionic eminence and olfactory bulb, it is only expressed in a fraction of the cells of the subventricular zone of the cerebral cortex. Qualitatively, the expression pattern in the cerebral cortex is different from that in the olfactory bulb and lateral ganglionic eminence. The DLX-2-positive cells in the cerebral cortex and olfactory bulb either arise de nova, or represent cells that have migrated from other DLX-2-positive regions such as the ganglionic eminence. In either possibility, they represent an extension of expression domain II of DLX-2 into these regions.
Previous Northern analysis showed that Dlx-2 mRNA is expressed in the adult forebrain (Porteus et al., 1991 (Porteus et al., , 1992 ). Immunohistochemistry shows the cells in the adult brain that express DLX-2 protein. Figure 4 demonstrates that at E16.5, DLX-2 is expressed along the entire subventricular zone from the ganglionic eminence to the olfactory bulb. We observe this same pattern of expression from the ganglionic eminence to the olfactory bulb at P17 and in the adult forebrain (Fig. 5) . Through development the proportion of DLX-2-expressing cells decreases but after E 16.5 there is a stream of cells that begins in a region corresponding to a subventricular zone of the primordia of the caudoputamen complex that travels beneath the corpus callosurn (when it is present) over the striatum, and terminates in the olfactory bulb. Figure 5 demonstrates this cell stream at P17 and in the adult.
DLX-2'is expressed in the distal ectoderm of embryonic outgrowths Dlx-2 was originally named Tes-I (telencephalon embryonic subtraction) because of its temporal regulation in the development of the telencephalon. It was renamed Dlx-2 because it belongs to a family of vertebrate genes that share homology in the homeobox to the distal-less gene of Drosophila. The first reports describing the members of the Dlx family noted that the expression pattern of the mammalian and fly genes did not seem to be related (Porteus et al., 199 1; Price et al., 199 1) . Since that time, however, we and others have found that Dlx-1 and Dlx-2 are expressed in structures of the mouse embryo that correspond to analogous Drosophila structures where distal-less is expressed (Cohen, 1990; Bulfone et al., 1993a) . Figures 2 and 6 develop this concept further by showing DLX-2 expression in the distal ectodermal layer of a number of structures during embryogenesis including the limbs, branchial arches, tail, genital tubercle, and frontonasal prominence (pose). All of these structures bud from the core of the embryo and in each case DLX-2 expression in the ectoderm outlines the bud, with maximal expression in the most distal ectoderm. DLX-2 is directly expressed with MASH-I and inversely expressed with MAP-2 in the medial ganglionic eminence As shown in previous sections, DLX-2 expression is spatially restricted along the longitudinal and transverse axes. Likewise, Figure 2 . DLX-2 expression at ElO.5. The top panel shows DLX-2 expression in a parasagittal section of a mouse E10.5 head by immunohistochemistry. The letters B, C, and D in the top panel are regions shown at higher magnification in panels B, C, and D, these letters are in roughly the same relative location in the higher-magnification panels as in the lower-magnification panel. The arrows in the top panel mark borders between the lateral ganglionic eminence and cerebral cortex and between the ventral thalamus and dorsal thalamus. With reference to the lower-magnification panel, B is rotated 90" counterclockwise, C is rotated 45" counterclockwise, and D is rotated 90" clockwise. In B, the border of DLX-2 expression between the lateral ganghonic eminence and cerebral cortex is marked with an arrow. C demonstrates a continuum of DLX-2 expression from domains I and II through the region of the optic stalk at E10.5. In D, the region of the zona limitans (ZL) is marked with an arrow. The staining of the tectum and cerebellar anlage in the top panel is artifactual. it is spatially restricted along the ventricular-pial axis-a major axis of cell differentiation. An important feature of DLX-2 expression from E10.5 until E18.5 is that apparently all of the cells in the subventricular layer express DLX-2. This ubiquity of expression is deduced from visual inspection and comparison of DLX-2 expression with 4',6-diamidino-2'-phenylindole (DAPI) counterstaining on nuclei (data not shown). This result implies that as cells migrate from the ventricular zone to the mantle, they all express DLX-2 at some point in their development. To begin to define when during differentiation DLX-2 is expressed, we compared its expression with markers for different stages of neural differentiation. The three other markers we used were MASH-1, a protein expressed in the early stages of neuronal differentiation (Lo et al., 199 1; Guillemot et al., 1993) MAP-2, a protein expressed in terminally differentiated neurons (Garner et al., 1988) , and the incorporation of BrdU into nuclei undergoing DNA synthesis.
We compared the expression of DLX-2, MASH-l, and MAP-2 by performing immunohistochemistry on adjacent sagittal sections of tan E 12.5 mouse embryo (Fig. 7) . In general, our study of MASH-1 confirmed the results of Lo et al. (199 1) and Guillemot and Joyncr (1993) . Specifically, in the CNS we found MASH-l expression in cell nuclei of discrete domains of the spinal cord, midbrain, and forebrain. In the forebrain rostra1 to the zona limitans, it is expressed in an apparently identical pattern to DLX-2. Within the ganglionic eminence, MASH-l is expressed strongest in most, if not all, cells of the subventricular zone, and weaker in scattered cells of the ventricular zone and in cells in the region covering the subventricular zone. We call this latter region the ganglionic submantle (GSM) because it lies between the mantle and the subventricular zones. DLX-2 is expressed in the same pattern in the ganglionic eminence. Using double immunofluorescence (Fig. 8 ), it appears that most cells within the ganglionic eminence that express one gene also express the other. In the context of the entire embryo, therefore, there are regions that express DLX-2 and MASH-l independently. Within the E10.5-E12.5 forebrain, however, these genes are expressed in the same cells.
Consistent with previous studies (Gamer et al., 1988) , we found that MAP-2 is non-nuclear and expressed strongest in cells closest to the pial surface, also known as the mantle (Fig.  7) . In the ganglionic eminence, it is expressed in the ganglionic mantle (GM) (Fig. 7) . The ganglionic mantle is the region where cells are expected to be the most mature based on the known pattern of differentiation in the forebrain. Cells in the ganglionic submantle express MAP-2 at a lower level than in the mantle, and MAP-2 is essentially not expressed in the subventricular or ventricular zones. MAP-2 and DLX-2 have complementary expression patterns. In the area of highest DLX-2 expression, the subventricular zone, we see no MAP-2 expression. Conversely, in the region showing highest MAP-2 expression, the ganglionic mantle, we see no DLX-2 expression. In the ganglionic submantle there is both DLX-2 expression and MAP-2 expression, although at submaximal levels. Since DLX-2 expression is seen in essentially all cells of the ganglionic submantle, it is clear that there are cells that express both DLX-2 and MAP-2 concurrently in this zone. Identical results are found in other regions of DLX-2 expression in the forebrain, in particular, the preoptic area, the suprachiasmatic nucleus, and the ventral thalamus (Fig. 7) .
Is DLX-2 expressed in mitotically active cells? As a putative regulator of differentiation, we wished to establish whether DLX-2 was present in mitotically active cells. To test this idea, we labeled cells undergoing S-phase of the cell cycle in E12.5 mouse embryos with a pulse of 5-bromo-2'-deoxyuridine (BrdU) and compared the location of BrdU-labeled cells, with the expression of DLX-2 on adjacent sections. In the forebrain BrdU-positive cells lie in the S-phase region of the ventricular zone and in the subventricular zone (Takahashi et al., 1993) . These BrdU-positive cells form a continuous layer (Fig.  9) . The zone of BrdU labeling and DLX-2 labeling overlap but do not superimpose on each other (Fig. 9) . Since essentially all cells in the DLX-2 layer express DLX-2 and, similarly, essentially all cells in the BrdU layer are BrdU positive, it is likely that there are cells positive for both BrdU and DLX-2 in the region where the zones overlap. Conversely, in the regions of the zones that do not overlap, there are cells that are labeled by only one marker. In the ventricular zone, we also observe discrete clusters of DLX-2-positive cells. Some of these are radially aligned, and appear as strings of single cells (Fig. 9 ) while others are arranged as grape-like clusters (data not shown).
Discussion
Dlx-2 is a vertebrate homeobox gene that is among a new set of genes that have restricted spatial and temporal patterns of expression in the mammalian forebrain (Bulfone et al., 1993a; reviewed in Puelles and Rubenstein, 1993; Rubenstein and Puelles, in press ). Previously, we have characterized the expression of Dlx-2 using in situ RNA hybridization (Porteus et al., 199 1, 1992; Bulfone et al., 1993a Bulfone et al., , 1993b . In this article we describe an antiserum against DLX-2 that we use to characterize its expression further. These studies are the first use of immu- nohistochemistry to characterize homeodomain protein expression in the mammalian embryonic forebrain, which greatly improved the sensitivity and resolution of our analysis and, consequently, revealed four new results: (1) DLX-2 is expressed in the distal ectoderm of structures that bud from the embryo; (2) DLX-2 expression persists in two domains in the embryonic forebrain, but expression in domain II expands into the olfactory bulb and cerebral cortex at later stag& (3) DLX-2 is expressed in periventricular cells in a stream from the ganglionic eminence to olfactory bulb in the embryo, newborn, and adult; (4) BrdU incorporation into S-phase cells, and the expression of DLX-2, MASH-1, and MAP-2 identify molecularly distinct populations of cells within the wall of the basal telencephalon and provide a basis for a model of stages of cellular differentiation.
DLX-2 expression in the distal ectoderm of appendages and other structures
Previously we reported that Dlx-2 and DIl are expressed in analdgous structures of the mouse and fly: the embryonic brain, limbs, and face (Bulfone et al., 1993b) . Mutations of the distalless gene in Drosophila disrupt development along the proximaldistal axis of limbs Cohen, 1990; Vachon et al., 1992 ). Here we show that DLX-2 is expressed in the distal ectodermal cells of outgrowths from the embryo: the branchial arches, limb buds, frontonasal prominence, tail, and genital tubercle. The distal expression of DLX-2 suggests that Dlx-2, like its fly homolog distal-less, may play a role in establishing the proximal-distal axis in these developing structures. Molecular studies of limb development have implicated a variety of growth factors and homeobox genes in the regulation of patterning and differentiation (Tabin, 199 1; Izpisua-Belmonte and Duboule, 1992; Song et al., 1992; Niswander and Martin, 1993; Zakany and Duboule, 1993) . For example, ectopic expression in the embryonic limb ofHox-D genes, which normally are expressed in overlapping patterns in the limb mesenchyme, cause predictable limb malformations (Morgan et al., 1992) . DIx-2, as well as Dlx-1 (Dolle et al., 1992) , is expressed in the distal ectodermal portion of the limb bud. Similar to the developing limb bud, in the genital tubercle DZx-2 is expressed in the ectodermal cells surrounding a mesenchyme that has a graded pattern of expression of genes from the Hox-D locus (Dolle et al., 1991) . Moreover, DZx-2 is linked to the Hox-D cluster on mouse and human chromosome 2 (McGuinness et al., 1992; Ozcelik et al., 1992) . The structural and conserved expression relationship suggests that there may be a common gene cassette, similar in concept to that discussed by Jan and Jan (1993) , involving the Dlx and Hox-D genes. This gene cassette may be a common developmental program involving a particular set of genes used in multiple structures to accomplish a specific purpose. For Dlx-2 and Hox-D, that purpose may be to regulate differentiation and morphogenesis in outgrowths from the embryo such as the limbs and genital tubercle. in adjacent parasagittal sections from a mouse E12.5 embryo. The left panels show MASH-l expression, the middle panels show DLX-2 expression, and the right panels show MAP-2 expression. The bottom two rows are higher-magnification views of the same section shown in the top row. The subventricular zone (9'2) shows strong MASH-l and DLX-2 labeling but no MAP-2 labeling. The ganghonic mantle (GM), conversely, shows no DLX-2 and MASH-l labeling but strong MAP-2 labeling. In the ganglionic submantle (GSM), cells are labeled with intermediate levels of both DLX-2 and MAP-2. In the top row, similar intermediate levels of DLX-2 and MAP-2 staining can also be seen in the ventral thalamus, the preoptic area, and the suprachiasmatic nucleus. Scale bar: 350 pm for the top row, 140 pm for the bottom two rows.
DLX-2 expression in the embryonic basal telencephalon extends into the cerebral cortex and the olfactory bulb Prior descriptions of Dlx-2 expression have emphasized that there are several sharp boundaries of expression, as exemplified at the zona limitans, the border between the ventral thalamus and dorsal thalamus (Porteus et al:, 1991; Bulfone et al., 1993 a,b) . Consistent with these results, we found no evidence of DLX-2 expression in the dorsal thalamus (Figs. 2, 3) . Thus, the zona limitans is an example of one of the distinct borders of DLX-2 expression that is present throughout development. In contrast, early in development (E9.5-E12.5) there is a border of DLX-2 expression between the lateral ganglionic eminence on one side, and the cerebral cortex and the primordia of the olfactory bulb on the other. By E16.5, however, DLX-2 expression extends into the olfactory bulb and cerebral cortex (Fig.  2) . Thus, there are extensions of DLX-2 expression domains later in development.
One of the distinguishing features of DLX-2 expression late in gestation is the stream of DLX-2-positive cells that spans the periventricular region of the rostralmost part of the ganglionic eminence/basal ganglia to the olfactory bulb. This stream ofDLX-2-positivecellsis present from E16.5 to theadult. Dlx-I may be expressed along the same stream of cells (Salinas and Nusse, 1992) . In our studies it is difficult to distinguish between the possibility of de novo expression in cells of the olfactory bulb or an origin from DLX-2-expressing cells in the lateral ganglionic eminence and a subsequent migration into the olfactory bulb.
There are two sets of studies that give circumstantial evidence that DLX-2-expressing cells migrate into the olfactory bulb. The first line of studies demonstrate a migratory pathway between from the anterior subventricular zone of the lateral ventricle to the olfactory bulb (Hinds, 1968; Altman, 1969; Bayer, 1983; Luskin, 1993) . Luskin (1993) used retroviral labeling experiments to demonstrate a migratory pathway from the anterior subventricular zone, an area bordered by the cerebral cortex and lateral ganglionic eminence, into the olfactory bulb. The pathway of migration into the olfactory bulb corresponds to the position where DLX-2 is expressed late in development and in the adult mouse. The second line of studies is the migration of luteinizing hormone-releasing hormone (LH-RH)-producing cells. These cells are born in the olfactory placode and then migrate into the brain through the olfactory bulb to their final destination in the hypothalamus (Schwanzel-Fukuda and Pfaff, 1989,199O; Wray et al., 1989) . DLX-2 is expressed in the olfactory placode, olfactory bulb, and hypothalamus and thus labels much of this migratory pathway. It may be that cells migrating along this pathway express DLX-2. This pathway of LH-RH cell migration is in the opposite direction than the migration from the anterior subventricular zone to the olfactory bulb described above. Thus, there are bidirectional migrations m DLX-2-expressing domains of the basal telencephalon, suggesting that DLX-2-expressing cells may migrate.
In addition, DLX-2-expressing cells are present in the cerebral cortex. These DLX-2-expressing cells are sparsely dispersed in various layers. Cortical DLX-2-positive cells are seen next to the lateral ganglionic eminence, but are lacking near the septum, which also expresses DLX-2. These cells may be born in the cerebral cortex or arise by migration from the ganglionic eminence. Fishell et al. (1993) have evidence for a barrier to migration between these two zones because DiI-labeled ventricular zone cortical cells, which do not express DLX-2, do not readily migrate into the ganglionic eminence. On the other hand, migration between these two zones may occur at layers other than the ventricular zone, in particular, the subventricular, intermediate, or mantle zones. Recently, O'Rourke et al. (1992) have observed tangential cell movement within the subventricular and intermediate zones of the cerebral cortex. Furthermore, Walsh and Cepko (1993) have shown that there is widespread clonal dispersion in the cerebral cortex, emphasizing the existence of tangential migrations within the cortex. Finally, Halliday and Cepko (1992) have stated that within the subventricular zone of the ganglionic eminence there is tangential movement. Since essentially all subventricular zone cells of the medial and lateral ganglionic eminence express DLX-2, Halliday and Cepko's studies suggest that DLX-2-expressing cells are capable of tangential movement. Further studies will establish whether there are cell migrations within the subventricular, intermediate, or mantle zones from the ganglionic eminence or olfactory bulb to the neocortex. DLX-2 expresslon In the adult brain In the adult brain there is a set of DLX-2-expressing cells along the surface of the striatum, under the corpus callosum, that extend into the olfactory bulb. The adult DLX-2-expressing cells lie in a region that corresponds to a proliferative zone in the embryo. Morphologically, the DLX-2-expressing cells are small with a large nuclear to cytoplasmic ratio similar to the DLX-2-expressing cells in the embryo. Thus, the adult DLX-2-expressing cells share similar characteristics to the immature embryonic DLX-2-expressing cells. Recently, neuronal stem cell lines have been established from the adult brain using different mixtures of purified growth factors (Ronnett et al., 1990; Reynolds and Weiss, 1992; Richards et al., 1992) . These studies suggest that either these growth factors can induce dedifferentiation of mature neurons or that there is a population of undifferentiated cells in the adult brain that can give rise to neurons. The newly developed cell lines, therefore, may have been derived from DLX-2-expressing or similarly less differentiated cells present in the adult brain.
A separate issue is what the cell types are in the adult brain that arise from DLX-2-expressing cells. There are two pieces of evidence that some DLX-2-expressing cells are part of the neuronal lineage, The first is that DLX-2 is coexpressed with MAP-2, a marker of terminal neuronal differentiation. The second is that DLX-2 is expressed in essentially every cell of the Figure 9 . Comparison of DLX-2 expression with S-phase of the cell cycle. This figure shows DLX-2 expression and bromodeoxyuridine (BrdU) incorporation in adjacent coronal sections from an E12.5 mouse that had been injected with BrdU 1 hr before sacrifice. The top row, labeled B, shows BrdU incorporation, and the bottom row, labeled D, shows DLX-2 expression. The right column is a higher magnification of a region of the medial ganglionic eminence from the left column. In the right column, the lateral ventricle (LV') is labeled. At the bottom the span of dense BrdU incorporation (labeled B and dense DLX-2 expression (labeled D) is marked. In summary, this figure demonstrates that cells that express DLX-2 overlap with cells that are still undergoing S-phase of the cell cycle. Scale bar: 400 pm for the left panels, 25 rrn for the right panels. subventricular zone and ganglionic submantle during a period of active neurogenesis and limited gliogenesis.
Late in gestation and postnatally, DLX-2 is expressed in the subventricular zone of the cerebral cortex and striatum. Several studies have suggested that the fate of postnatal subvcntricular zone cells is to become oligodendrocytes (Altman, 1966; Imamoto et al., 1978; Levine and Goldman, 1988a,b; Hardy and Reynolds, 199 1; Levison and Goldman, 1993) . Recently, Levison and Goldman (1993) have demonstrated that both oligodendrocytes and astrocytes develop from progenitors in the rat postnatal subventricular zone. Therefore, it is likely that DLX-2-expressing cells in the postnatal subventricular zone give rise to glia. Conclusive evidence for DLX-2 expression in the glial lineage will come either by staining purified populations of cells that are known to be part of the glial lineage or by double labeling with glial-specific markers. Nonetheless, DLX-2 is probably expressed in both neuronal and glial lineages.
Molecularly distinct populations in the developing ganglionic eminence During development, cells pass through various stages of differentiation, a process that may or may not be accompanied by overt morphologic change. Implicit is that the changes involved in differentiation are molecular and are reflected in the composite of gene expression at a given stage. Previously, the state of differentiation of a cell in the forebrain has been deduced from its spatial location along the ventricular-pial or radial axis and its morphology. Thus, cells in the ventricular zone are more undifferentiated than those in the subventricular zone, which are more undifferentiated than those in the mantle zone. But, as in hematopoiesis, differentiation may occur without change in spatial location and be unrecognized using a spatial and/or morphologic classification. Similarly, cells of different lineages can not be distinguished based on their spatial location during development. That is, as in the hematopoietic system, cells of different lineages may be neighbors. Molecular markers can be used to resolve different lineages or stages of differentiation. In this study we believe we use markers of different stages of differentiation rather than of different lineages for two reasons. First, these markers are expressed in essentially 100% of the cells of particular regions. For example, DLX-2 is expressed in essentially all cells of the subventricular zone and ganglionic submantle, and MAP-2 is expressed in essentially all cells of the mantle zone at E12.5. It is possible that a given region contains only a single lineage, but we believe it is more likely that the markers are lineage nonspecific. Second, MAP-2, MASH-1, and the incorporation of BrdU are known to be lineagenonspecific markers (Gamer et al., 1988; Guillemot et al., 1993) .
Based on our analysis of the expression patterns of DLX-2, MASH-l, and MAP-2 and the incorporation of BrdU into S-phase of mitotic cells, we can define four molecularly distinct populations of cells within the ganglionic eminence (Table 2) . This table identifies the molecular characteristics of four populations of cells in the ganglionic eminence identified in this study. "POP"-Population number; "LCKY--location within the ganglionic eminence; "BRDU"-intensity of BrdU staining; "DLX-2"--intensity of DLX-2 staining; "MASH-l"-intensity of mash-l staining; "MAP-2"-intensity of MAP-2 staining.
Population I cells reside in the ventricular zone, are actively mitotic, and do not express DLX-2 or MASH-l. Within population I cells are either labeled or unlabeled by BrdU, depending on what part of the cell cycle they are in. The strong band of BrdU labeling in the ventricular zone reflects the known pattern of interkinetic nuclear migration of mitotically active ventricular zone cells (Takahashi et al., 1993) . This population contains cells that are the early progenitors of the developing ganglionic eminence. Population II cells express DLX-2 and MASH-l but do not express MAP-2. As in population I, population II cells will show a heterogeneity in BrdU labeling, depending on when in the cell cycle they are examined. The majority of population II cells reside in the subventricular zone but an important fraction are found in the ventricular zone. Population II ventricular zone cells can be seen as radially aligned columns of cells in Figure  9 . We hypothesize that population II cells in the ventricular zone are in the process of moving into the subventricular zone. The existence of population I and II cells in the ventricular zone highlights the possibility of heterogeneity of cell types and/or stages within a given region. Further, population II cells highlight the possibility that cells in different regions may be molecularly identical.
Studies by McConnell and Kaznowski (199 1) emphasize the importance of the milieu in which a cell undergoes its final S-phase as an important determinant for the cell's final laminar location in the developing cerebral cortex. While we have not demonstrated that cells do not undergo mitosis after passing through population II, it is plausible that population II may be stages when master regulatory genes, such as Mash-1 and Dlx-2, imprint their effects on cells undergoing their final mitosis and complete the process of differentiation.
Population III cells express DLX-2, MASH-1 and MAP-2 at intermediate levels and do not incorporate BrdU. Population III cells primarily reside in the ganglionic submantle, a layer between the subventricular and mantle zones. There may also be some population III cells in the subventricular zone that are beginning to migrate into the ganglionic submantle. We hypothesize that cells in population III are in the midst of a transition from relatively undifferentiated stages, characterized by high levels of DLX-2 and MASH-l expression, to stages of terminal differentiation, characterized by high levels of MAP-2 In summary, we propose that the four populations correspond to four different stages of differentiation in the ganglionic eminence. Generally the four stages of differentiation have distinct positions along the ventricular-pial axis, but populations I and II highlight the possibility that differentiation may occur without change in location. We imagine, in fact, that cells undergo more than three transitions and, within any given spatial location, may undergo multiple molecular transitions. We hope that this model provides the beginning of a framework for understanding the different stages ofneuronal differentiation in the mammalian forebrain. This framework should help in the interpretation of experiments that study the effect of altering the function or expression of genes that regulate forebrain development.
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